HomeStock SectorsBioTechWhy Is Dyne Therapeutics...

Why Is Dyne Therapeutics Stock Trading Lower On Tuesday? – Dyne Therapeutics (NASDAQ:DYN)

Dyne Therapeutics, Inc. DYN stock is trading lower after the company announced on Tuesday that it had revised the ongoing Registrational Expansion Cohort in the Phase 1/2 ACHIEVE trial for DYNE-101 for myotonic dystrophy type 1 (DM1).

The primary endpoint is a change from baseline in middle finger myotonia as measured by vHOT at 6 months, compared to placebo.

  • Video hand opening time (vHOT) measures hand function and myotonia (delayed relaxation of skeletal muscles after voluntary contraction).

Secondary endpoints include change from baseline in splicing as measured by the composite alternative splicing index (CASI-22), muscle strength as assessed by Quantitative Muscle Testing (QMT), performance on both the 10-Meter Walk/Run Test (10MWR) and 5 Times Sit to Stand Test (5xSTS), and the Myotonic Dystrophy Health Index (MDHI) patient-reported outcome measure, all at 6 months compared to placebo.

Also Read: JPMorgan Seeks Clarity On Dyne Therapeutics’ DYNE-101 Expansion, Regulatory Path

The cohort is expected to enroll 60 participants, randomized 3:1 to receive DYNE-101 6.8 mg/kg Q8W or placebo. Dyne plans to complete enrollment in the Registrational Expansion Cohort in the fourth quarter of 2025.

Dyne intends to use data from the Registrational Expansion Cohort and the already enrolled patients in the multiple ascending dose (MAD) and ongoing long-term extension portions of the ACHIEVE trial to support a potential submission for Accelerated Approval in the U.S.

Data from the cohort are planned for mid-2026 to support a potential U.S. Accelerated Approval submission in late 2026.

It seems that the company’s stock plunged as earlier Dyne expected to submit an Accelerated Approval Biologics License Application (BLA) in the first half of 2026.

Dyne plans to initiate a confirmatory Phase 3 clinical trial in Q1 2026.

Dyne also reported new long-term data from adult DM1 patients enrolled in the randomized, placebo-controlled MAD portion of the DYNE-101 ACHIEVE trial, including data from the 6.8 mg/kg Q8W cohort (n=6) at up to 12 months.

At the registrational dose of 6.8 mg/kg Q8W, DYNE-101 demonstrated robust and sustained improvement in myotonia as measured by vHOT and sustained improvements across multiple other endpoints.

  • As previously disclosed, treatment with DYNE-101 led to an improvement in vHOT of 3.3 seconds compared to placebo at 6 months.
  • New data demonstrated that mean improvements at 6 months were sustained at 12 months for vHOT, 10MWR, 5xSTS, MDHI, and QMT, which demonstrated a 10% improvement in strength at 6 months, increasing to 20% at 12 months relative to baseline.

The company expects that its $677.5 million cash, cash equivalents, and marketable securities as of March 31, 2025, will be sufficient to fund its operations into the fourth quarter of 2026.

The U.S. Food and Drug Administration (FDA) on Tuesday granted Breakthrough Therapy Designation to DYNE-101 for DM1.

Price Action: DYN stock is trading lower by 18.2% to $11.30 at last check Tuesday.

Read Next:

Image via Shutterstock

Most Popular

More from Author

Why Is Cogent Biosciences Stock Trading Higher On Monday? – Cogent Biosciences (NASDAQ:COGT)

Cogent Biosciences, Inc.‘s COGT bezuclastinib showed meaningful clinical benefit for patients with...

3 Bullish Setups to Watch in July Amid Seasonal Tailwinds

As the second half of the year begins, several bullish setups...

The Energy Report: Listen to What OPEC Says

prices are shaking off a larger-than-expected OPEC production increase as...

Why Is KalVista Pharmaceuticals Stock Soaring On Monday? – KalVista Pharma (NASDAQ:KALV)

The U.S. Food and Drug Administration (FDA) on Monday approved KalVista...

Read Now

Why Is Cogent Biosciences Stock Trading Higher On Monday? – Cogent Biosciences (NASDAQ:COGT)

Cogent Biosciences, Inc.‘s COGT bezuclastinib showed meaningful clinical benefit for patients with non-advanced systemic mastocytosis, a rare and debilitating immune disorder. With statistically significant improvements across all endpoints—including symptom reduction and biomarkers of mast cell activity—the data support the company's plan to file for Food and Drug Administration...

3 Bullish Setups to Watch in July Amid Seasonal Tailwinds

As the second half of the year begins, several bullish setups are emerging—each supported by seasonal patterns and historical data. is approaching multi-year highs following a strong June, while technical signals in the broader market and semiconductor sector point to continued momentum. Meanwhile, recent policy developments may...

The Energy Report: Listen to What OPEC Says

prices are shaking off a larger-than-expected OPEC production increase as the precious metals get hit by a ton of bricks after President Trump posted about new tariffs on BRIC Nations on his Truth Social account. Yet despite the talk about OPEC wanting to maintain its market share,...

Why Is KalVista Pharmaceuticals Stock Soaring On Monday? – KalVista Pharma (NASDAQ:KALV)

The U.S. Food and Drug Administration (FDA) on Monday approved KalVista Pharmaceuticals Inc.’s KALV Ekterly (sebetralstat) for acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.Ekterly is the first and only oral on-demand treatment for HAE. HAE is characterized by recurrent...

Dow Jones Forecast: Political Tensions and Tariff Risks Weigh on Outlook

US futures are rising on Monday after the extended holiday weekend. Uncertainty surrounding U.S. trade tariff policies are keeping investors cautious, whilst Tesla (NASDAQ:) is taking a hit after Musk announced plans to launch a political party.US Futures 0.78% at 44839 0.7% at 6266 0.53% at 23977In...

Why Is Apogee Therapeutics Stock Soaring On Monday? – Apogee Therapeutics (NASDAQ:APGE)

Apogee Therapeutics Inc. APGE stock is experiencing a significant surge, trading almost 29% higher in premarket on Monday.This substantial increase in stock price follows the release of positive 16-week data from Part A of the Phase 2 APEX clinical trial of APG777, an anti-IL-13 antibody, for moderate-to-severe...

EUR/USD Slips as Trade Talks Stall and Retail Sales Disappoint

falls with trade talks in focus and following weak retail sales. Oil slips after OPEC+ increases output by more than expected.EUR/USD Falls With Trade Talks in Focus and After Weak Retail SalesThe EU and the US are nearing a framework agreement Eurozone retail sales fell -0.7% MoM EUR/USD...

Oil Prices Expected to Stay Under $70

Analysts widely expect oil prices to remain below $70 per barrel for the remainder of 2025, primarily due to global oversupply and ongoing uncertainties regarding demand. Despite heightened geopolitical tensions in the Middle East, these factors are not anticipated to significantly drive up oil prices unless direct supply...

Markets Await Trade Deals as Trump Makes New Tariff Threats

Dollar edges higher, gold slips despite confusion and renewed trade tensions Trump delays tariff deadline to August 1, says trade deals are close Wall Street hits record after Congress passes Big Beautiful Bill Oil recovers from lows after OPEC+ hikes output more than expected New Threats and ExtensionsThe dreaded July 9...

Gold Prices Under Pressure as Tariff Talks Offset Geopolitical Risks

Tariff Negotiations Weigh Down on Gold Gold () rose slightly on Friday as markets adjusted amid evolving trade headlines. However, it pulled back during the day as traders monitored negotiations with key U.S. trade partners, many aiming to finalise deals or secure more time ahead of approaching deadlines....

Oil Price Retreats but Bullish Technicals Suggest Upside Ahead

The NA session kicks off quietly, with subdued volumes as American traders take the day off, giving markets a breather after the upside surprise in the last week and fresh diplomatic updates from the US. From a price action perspective, has been consolidating in a narrow...

Stocks Week Ahead: Can Small-Business Optimism, Inflation Clues Keep Bulls Alive?

There’s not much on this week’s economic calendar. The only big event was supposed to occur on Wednesday, July 9. That would have been 90 days after President Donald Trump postponed his April 2 reciprocal tariffs on America’s trading partners on April 9 for 90 days. Today,...